التفاصيل البيبلوغرافية
| العنوان: |
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. |
| المؤلفون: |
Motzer, Robert, George, Saby, Merchan, Jaime R, Hutson, Thomas E, Song, Xun, Perini, Rodolfo F, Xie, Ran, Bapat, Urmi, Puente, Javier |
| المصدر: |
Oncologist; Jun2023, Vol. 28 Issue 6, p501-509, 9p, 3 Charts, 3 Graphs |
| مصطلحات موضوعية: |
PREVENTION of drug side effects, RENAL cell carcinoma, HYPERTENSION, DIARRHEA, HYPOTHYROIDISM, SOCIAL support, NAUSEA, ANTINEOPLASTIC agents, MUSCULOSKELETAL pain, PROTEINURIA, RESEARCH funding, FATIGUE (Physiology), PATIENT safety, VOICE disorders |
| مستخلص: |
Background Lenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used CLEAR data to characterize common adverse reactions (ARs; adverse-event preferred terms grouped in accordance with regulatory authority review) associated with lenvatinib plus pembrolizumab and review management strategies for select ARs. Materials and Methods Safety data from the 352 patients who received lenvatinib plus pembrolizumab in the CLEAR study were analyzed. Key ARs were chosen based on frequency of occurrence (≥30%). Time to first onset and management strategies for key ARs were detailed. Results The most frequent ARs were fatigue (63.1%), diarrhea (61.9%), musculoskeletal pain (58.0%), hypothyroidism (56.8%), and hypertension (56.3%); grade ≥3 severity ARs that occurred in ≥5% of patients were hypertension (28.7%), diarrhea (9.9%), fatigue (9.4%), weight decreased (8.0%), and proteinuria (7.7%). Median times to first onset of all key ARs were within approximately 5 months (approximately 20 weeks) of starting treatment. Strategies for effectively managing ARs included baseline monitoring, drug–dose modifications, and/or concomitant medications. Conclusion The safety profile of lenvatinib plus pembrolizumab was consistent with the known profile of each monotherapy; ARs were considered manageable with strategies including monitoring, dose modifications, and supportive medications. Proactive and prompt identification and management of ARs are important for patient safety and to support continued treatment. Clinicaltrials.gov ID NCT02811861 [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder